Abstract
Rectus sheath hematoma (RSH) is a condition caused by hemorrhage into the rectus sheath. A 61-year-old man with end-stage renal failure and rheumatoid arthritis presented with abdominal pain following biweekly self-injections of certolizumab pegol. Computed tomography (CT) demonstrated a large high-density left-sided RSH. Due to exacerbating pain, transcatheter arterial embolization (TAE) for the left inferior epigastric artery (IEA) was performed. This represents the first reported case of RSH caused by certolizumab pegol, highlighting risks associated with low abdominal fat, auto-injector use, and anticoagulant therapy in dialysis patients.
Introduction
Rectus sheath hematoma (RSH) is an accumulation of blood within the sheath of the rectus abdominis muscle, typically resulting from the rupture of the epigastric arteries or their branches. While RSH accounts for approximately 2% of acute abdominal pain cases in emergency settings, it is frequently misdiagnosed due to its rarity and clinical overlap with other abdominal pathologies.
In patients with rheumatoid arthritis (RA), the management of the disease often involves the self-administration of biologics via subcutaneous injection. However, comorbid conditions such as end-stage renal disease (ESRD) and physical limitations like joint deformities can complicate this routine procedure. This report details a unique case of RSH triggered by the self-injection of certolizumab pegol, a TNF-α inhibitor, in a patient with multiple risk factors.
Case Presentation
A 61-year-old male with a history of ESRD on hemodialysis and RA presented with acute abdominal pain. The patient had been performing biweekly self-injections of certolizumab pegol into his abdominal wall. Physical examination revealed a palpable, tender mass in the left lower abdomen.
Initial diagnostic imaging via computed tomography (CT) was performed to evaluate the source of the pain. The scan revealed a large, high-density mass within the left rectus sheath, confirming the diagnosis of a rectus sheath hematoma.
As the patient's pain intensified and hemoglobin levels dropped from 9.2 g/dL to 7.6 g/dL, the clinical team decided to proceed with an intervention to achieve hemostasis.
Intervention and Results
The patient underwent Transcatheter Arterial Embolization (TAE). During the procedure, angiography of the left inferior epigastric artery (IEA) was performed, which identified active contrast extravasation, indicating a persistent bleed.
The site was successfully embolized using a gelatin sponge. Following the procedure, the patient’s symptoms gradually resolved. To prevent recurrence, his dialysis anticoagulation protocol was temporarily adjusted to nafamostat mesylate, a drug with a shorter half-life than heparin. The patient was discharged after 10 days of recovery and was advised to rotate future injection sites to his thighs.
Discussion
This case underscores a "perfect storm" of factors that can lead to vascular injury during routine subcutaneous injections:
- The Auto-Injector Mechanism: Unlike manual syringes, auto-injectors utilize a fixed-depth needle. In patients with a low Body Mass Index (BMI)—this patient’s BMI was 17.7—the needle may penetrate beyond the subcutaneous fat layer, striking the underlying muscle or the inferior epigastric artery.
- Anticoagulation in ESRD: Patients on hemodialysis are at a baseline elevated risk for bleeding due to the routine use of anticoagulants like heparin. Furthermore, chronic kidney disease often leads to arteriosclerosis, making blood vessels more fragile.
- Physical Limitations of RA: Rheumatoid arthritis can cause significant joint deformity and loss of manual dexterity, making the precise handling of an auto-injector difficult and increasing the risk of accidental deep penetration.
- Anatomical Vulnerability: The IEA is particularly vulnerable below the arcuate line, where the posterior wall of the rectus sheath is absent, allowing hematomas to expand more freely into the preperitoneal space.
Conclusion
Clinicians should be aware of RSH as a potential complication of biologic self-injection, especially in thin patients or those on anticoagulation therapy. For high-risk individuals, manual syringes may offer better control over injection depth than auto-injectors. Additionally, educating patients on site rotation—specifically utilizing the thigh or shoulder instead of the abdomen—can mitigate the risk of serious vascular injury.
Summary updated